4.4 Article

Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling

Journal

DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 26, Issue 3, Pages 212-222

Publisher

WILEY
DOI: 10.1002/dmrr.1076

Keywords

diabetes; advanced glycation end product; receptor for AGE

Funding

  1. Chang Gung Memorial Hospital [CMRPD34017]
  2. National Science Council, Taiwan [NSC94-2320-b-180-021]

Ask authors/readers for more resources

Background Resveratrol (RSV) has been shown to ameliorate hyperglycaemia and hyperlipidaemia in streptozotocin-induced diabetic rats. In the present study, we examined the beneficial effects of RSV on diabetes mellitus (DM)-induced vasculopathy and explored its possible mechanism. Methods Male Sprague Dawley rats were injected with streptozotocin at 65 mg/kg body weight The induction of DM was confirmed by a fasting plasma glucose level >= 300 mg/dL and symptoms of polyphagia and polydipsia. The DM rats were treated with or without RSV at 0.75 mg/kg body weight three times a day for 4-8 weeks. Animals were sacrificed and vessel wall histology was examined by microscopy. The vascular smooth muscle cell activation was assessed by the medial thickness, collagen deposition, and the expressions receptor for advanced glycation end product, NF-kappa B, proliferation cell nuclear antigen, and the levels of Erk1/2 phosphorylation. Results In RSV-treated DM rats, the vascular wall thickening, collagen deposition/cross-linking, and vascular permeability were all alleviated compared with that of the untreated DM rats. The vascular smooth muscle cell of the RSV-treated rats was characterized with less proliferation, lower NF-kappa B, and Erk1/2 activation, decreased proliferation cell nuclear antigen and receptor for advanced glycation end product expression. Moreover, the plasma fructosamine was significantly reduced in RSV-treated DM rats. Conclusions RSV alleviated DM-induced vasculopathy through attenuation of advanced glycation end product receptor for advanced glycation end product NF-kappa B signalling pathway. Copyright (C) 2010 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available